FinasteridePosted by freemexy on August 8th, 2019 Finasteride tablets USP are contraindicated in the following: For interpretation of serial PSAs in men taking Finasteride tablets USP, a new PSA baseline should be established at least six months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on Finasteride tablets USP may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α-reductase inhibitor. Non-compliance with Finasteride tablets USP therapy may also affect PSA test results. To interpret an isolated PSA value in patients treated with Finasteride tablets USP for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men. These adjustments preserve the utility of PSA to detect prostate cancer in men treated with Finasteride tablets USP. Finasteride tablets USP may also cause decreases in serum PSA in the presence of prostate cancer. The ratio of free to total PSA (percent free PSA) remains constant even under the influence of Finasteride tablets USP. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing Finasteride therapy, no adjustment to its value appears necessary. Women should not handle crushed or broken Finasteride tablets USP when they are pregnant or may potentially be pregnant because of the possibility of absorption of Finasteride and the subsequent potential risk to a male fetus. Finasteride tablets USP are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed. [See Contraindications (4), Use in Specific Populations (8.1), Clinical Pharmacology (12.3), How Supplied/Storage and Handling (16)and Patient Counseling Information (17.2).] Like it? Share it!More by this author |